Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.4
Industry P/E
--
EV/EBITDA
-3.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$2.3
EPS
$-5.1
Face value
--
Shares outstanding
4,240,129
CFO
$-153.59 Mln
EBITDA
$-178.43 Mln
Net Profit
$-165.77 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
| -13.6 | -21.4 | -13.6 | -70.9 | -61.0 | -65.3 | -57.4 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
| -67.1 | -89.0 | 62.0 | -74.1 | -68.3 | -7.6 | 45.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
|
2.6 | 11.1 | 0.0 | -21.8 | -- | -180 | -- | 1.4 |
| 12.5 | 3,981.1 | 3,018.8 | 72.1 | 12.6 | -80 | 56.7 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,474.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 | |
| 37.7 | 3,099.9 | 158.3 | -68.9 | -29.3 | -113 | -- | 69.3 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate... is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932 Read more
President, CEO & Director
Mr. James V. Caruso
President, CEO & Director
Mr. James V. Caruso
Headquarters
Florham Park, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cellectar Biosciences Inc (CLRB) is $2.55 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Cellectar Biosciences Inc (CLRB) has given a return of -60.97% in the last 3 years.
Since, TTM earnings of Cellectar Biosciences Inc (CLRB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.57
|
1.26
|
|
2024
|
-0.01
|
0.03
|
|
2023
|
-0.04
|
-0.13
|
|
2022
|
-0.02
|
0.06
|
|
2021
|
-0.01
|
0.00
|
The 52-week high and low of Cellectar Biosciences Inc (CLRB) are Rs 20.60 and Rs 2.43 as of 04-Apr-2026.
Cellectar Biosciences Inc (CLRB) has a market capitalisation of $ 11 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cellectar Biosciences Inc (CLRB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.